Discover and read the best of Twitter Threads about #relatimab
Most recents (1)
With one day for the dust to settle, here are my thoughts on some of the #ASCO21 #melanoma data.
1) It is interesting to me that no adj PD-1 melanoma study has yet shown OS benefit vs comparator arm (CM238 - nivo vs ipi, S1404 - pembro vs HDI or ipi, KN054- pembro vs placebo).
1) It is interesting to me that no adj PD-1 melanoma study has yet shown OS benefit vs comparator arm (CM238 - nivo vs ipi, S1404 - pembro vs HDI or ipi, KN054- pembro vs placebo).
Is this because more time in f/u is needed to see diffs emerge? Or does it suggest that PD-1 is equally effective regardless of disease setting (adj vs metastatic) and that enough pts with metastatic melanoma have durable long-term control on PD-1 to explain lack of OS benefit?
I suspect that PD-1 does cure some melanoma pts in the adjuvant setting. But are these the same pts that would have been cured in the metastatic setting? Not easy to answer but longer f/u of these three pivotal studies will be very important.
